CIMT and taVNS for Hemiplegia in Infants
Primary Purpose
Infant Development, Hemiplegia, Constraint Induced Movement Therapy
Status
Active
Phase
Early Phase 1
Locations
United States
Study Type
Interventional
Intervention
transcutaneous auricular vagus nerve stimulation
Constraint induced movement therapy
Sponsored by
About this trial
This is an interventional device feasibility trial for Infant Development focused on measuring transcutaneous auricular vagus nerve stimulation, constraint induced movement therapy, infant hemiplegia
Eligibility Criteria
Inclusion Criteria:
Must have all of the following:
- 6-18 month-old infants with hemiplegia/motor asymmetry
- Must be able to participate in high intensity CIMT
- Gross Motor Function Classification System (GMFCS) level I-IV
Exclusion Criteria:
Must have none of the following:
- GMFCS level V
- severe motor impairment/quadriplegic involvement
- uncorrected blindness or deafness
- cardiomyopathy
Sites / Locations
- Medical University of South Carolina
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
CIMT + taVNS
Arm Description
The investigators will deliver taVNS paired with 40h of Constraint Induced Movement Therapy for unilateral weakness/hemiplegia
Outcomes
Primary Outcome Measures
CIMT fidelity
Feasibility of delivering high fidelity CIMT therapy sessions while the therapist is also triggering taVNS using the Fidelity of Implementation Measure (FIRM) with scoring range (0-4), higher scores indicate greater consistency of therapy with established CIMT procedure
Quality of Upper Extremity Skills Test (QUEST)
test of hand function and quality of movement between the right and left sides of the body, scoring range 0-100, higher scores indicate better hand function
Secondary Outcome Measures
Developmental Assessment of Young Children (DAYC) Physical Development domain
Developmental Assessment of Young Children, 2nd edition, physical domain is a standardized assessment of fine and gross motor skills, with a mean of 100 +/- 15
Goal Attainment Scale (GAS)
Goal Attainment Scale is an individualized standardized outcome measure that calculates the extent to which a patient's individual therapy goals are met, scored from -2 to +2 with higher scores indicating better than expected outcome, -2 indicating worse than expected outcome
Gross Motor Function Measure-66 (GMFM-66)
Gross Motor Function Measure-66 scores range from 0-3, with higher scores indicating better foundational gross motor skills and greater mastery of a task
Full Information
NCT ID
NCT05101707
First Posted
October 1, 2021
Last Updated
August 30, 2023
Sponsor
Medical University of South Carolina
Collaborators
National Center of Neuromodulation for Rehabilitation, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
1. Study Identification
Unique Protocol Identification Number
NCT05101707
Brief Title
CIMT and taVNS for Hemiplegia in Infants
Official Title
Combining taVNS With Early CIMT to Improve Health Outcomes of Infants With Unilateral Upper Extremity Weakness
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
April 1, 2022 (Actual)
Primary Completion Date
December 30, 2023 (Anticipated)
Study Completion Date
December 30, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Medical University of South Carolina
Collaborators
National Center of Neuromodulation for Rehabilitation, National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No
5. Study Description
Brief Summary
Newborns who are born premature or suffer brain injury at birth are at risk for motor problems that may cause weakness in reaching and grasping on one side of the body. In older children, therapists may use a hand mitt and restraint for the stronger arm, to encourage use of the weaker side, called constraint-induced movement therapy (CIMT). Even with the high intensity therapy of CIMT, it typically takes between 40-120 hours total treatment time for most children to improve their motor skills. A non-invasive form of nerve stimulation, transcutaneous auricular vagus nerve stimulation (taVNS), stimulates a nerve by the ear that enhances learning motor skills. The purpose of this study is to evaluate the safety and effectiveness of taVNS to improve motor skills when paired with CIMT in infants with one-sided weakness at 6-18months of age.
Detailed Description
Recent pioneering studies have used neuromodulation combined with intensive motor therapies in adults after stroke. Few studies have investigated combining neuromodulation and evidence-based pediatric intensive therapies such as CIMT, and then only in older children with CP to enhance neuroplasticity and improve functional outcomes. The investigators are the first to use non-invasive transcutaneous auricular vagus nerve stimulation (taVNS) paired with a motor task of bottle-feeding in infants with feeding failure. taVNS paired with motor feeding activity was safe and over 50% infants attained full oral feeds who were slated to receive a gastrostomy tube (G-tube). With the unique collaboration of experts in brain stimulation, pediatric translational clinical science and pediatric occupational therapy in this pilot project, the investigators propose to expand the paradigm of pairing neuromodulation with motor training in at-risk infants by exploring the safety, feasibility, and effectiveness of delivering taVNS concurrently with CIMT. The hypothesis is that combining taVNS with intensive CIMT may boost neuroplasticity, allowing for delivery of infant therapy at a minimally effective dosage while improving infant outcomes.
The investigators aim to determine the feasibility and safety of taVNS in at-risk infants 6-18mo undergoing CIMT therapy in open label pilot trial and assess both infant tolerability and the therapist's ability to deliver high-quality CIMT along with taVNS.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infant Development, Hemiplegia, Constraint Induced Movement Therapy
Keywords
transcutaneous auricular vagus nerve stimulation, constraint induced movement therapy, infant hemiplegia
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Model Description
CIMT plus taVNS
Masking
None (Open Label)
Allocation
N/A
Enrollment
5 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
CIMT + taVNS
Arm Type
Experimental
Arm Description
The investigators will deliver taVNS paired with 40h of Constraint Induced Movement Therapy for unilateral weakness/hemiplegia
Intervention Type
Device
Intervention Name(s)
transcutaneous auricular vagus nerve stimulation
Other Intervention Name(s)
taVNS
Intervention Description
Applying a pulsed microcurrent to the auricular branch of the vagus nerve, timed with motor activity of the weaker arm/hand
Intervention Type
Other
Intervention Name(s)
Constraint induced movement therapy
Other Intervention Name(s)
CIMT
Intervention Description
Applying a custom-made splint constraint to the stronger hand/arm to encourage use of the weaker hand/arm in intensive therapy sessions
Primary Outcome Measure Information:
Title
CIMT fidelity
Description
Feasibility of delivering high fidelity CIMT therapy sessions while the therapist is also triggering taVNS using the Fidelity of Implementation Measure (FIRM) with scoring range (0-4), higher scores indicate greater consistency of therapy with established CIMT procedure
Time Frame
0-1 month
Title
Quality of Upper Extremity Skills Test (QUEST)
Description
test of hand function and quality of movement between the right and left sides of the body, scoring range 0-100, higher scores indicate better hand function
Time Frame
0-2 months
Secondary Outcome Measure Information:
Title
Developmental Assessment of Young Children (DAYC) Physical Development domain
Description
Developmental Assessment of Young Children, 2nd edition, physical domain is a standardized assessment of fine and gross motor skills, with a mean of 100 +/- 15
Time Frame
0-2 months
Title
Goal Attainment Scale (GAS)
Description
Goal Attainment Scale is an individualized standardized outcome measure that calculates the extent to which a patient's individual therapy goals are met, scored from -2 to +2 with higher scores indicating better than expected outcome, -2 indicating worse than expected outcome
Time Frame
0-2 months
Title
Gross Motor Function Measure-66 (GMFM-66)
Description
Gross Motor Function Measure-66 scores range from 0-3, with higher scores indicating better foundational gross motor skills and greater mastery of a task
Time Frame
0-2 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
6 Months
Maximum Age & Unit of Time
18 Months
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Must have all of the following:
6-18 month-old infants with hemiplegia/motor asymmetry
Must be able to participate in high intensity CIMT
Gross Motor Function Classification System (GMFCS) level I-IV
Exclusion Criteria:
Must have none of the following:
GMFCS level V
severe motor impairment/quadriplegic involvement
uncorrected blindness or deafness
cardiomyopathy
Facility Information:
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
CIMT and taVNS for Hemiplegia in Infants
We'll reach out to this number within 24 hrs